[Federal Register Volume 79, Number 178 (Monday, September 15, 2014)]
[Notices]
[Pages 54987-54989]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-21856]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
A Novel Fusion Protein for Inhibiting HIV Budding
Description of Technology: Ubiquitin plays a critical role in HIV-1
budding. Vectors containing deubiquitin enzymes (DUbs) were constructed
to deliver DUbs to HIV-1 production sites in living cells. The DUbs
vectors comprise DUb cDNAs and cDNA expressing either HIV-1 gag, or the
ESCRT protein TSG101.
[[Page 54988]]
Experimental data show that the fusion proteins expressed by the
DUbs vectors retained their known protein-protein interactions and
caused a significant and specific interruption of HIV-1 budding. The
data suggest that the DUbs vectors could be used to inhibit HIV-1
infection or propagation in an individual. Thus, the DUbs vectors could
potentially be used in high-risk individuals to prevent HIV-1 infection
or as an adjunct therapy with known Anti-Retroviral Therapy (ART/HAART)
in infected individuals.
Potential Commercial Applications:
Prevention for HIV
Treatment for patients infected with HIV
Clinical research
Competitive Advantages:
Use for both treatment and prevention
No development of resistance to HIV
Development Stage: In vitro data available.
Inventors: Fadila Bouamr and Paola Sette (NIAID).
Publication: Sette P, et al. Ubiquitin conjugation to Gag is
essential for ESCRT-mediated HIV-1 budding. Retrovirology. 2013 Jul
29;10:79 [PMID 23895345].
Intellectual Property: HHS Reference No. E-223-2014/0--U.S.
Provisional Application No. 62/030,193 filed 29 July 2014.
Licensing Contact: John Stansberry, Ph.D.; 301-435-5236;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize the DUbs vectors and/or the fusion
proteins expressed by the vectors. For collaboration opportunities,
please contact Fadilla Bouamr, Ph.D. at [email protected].
Surgical Tool for Subretinal Tissue Implantation
Description of Technology: The invention pertains to a surgical
tool for implanting a sheet of tissue into the eye in such a way that
damage to the tissue and the eye during insertion and manipulation of
the tissue is minimized. The device enables tissue to be released and
delivered in a precise and controlled fashion. The device includes a
hollow handle portion (e.g. a syringe) with a bore fashioned to convey
fluid. An injector is fluidically coupled to the handle of the device
and includes a flat triangular shaped tip that defines an aperture
connected to the internal channel of the injector portion and
configured to enshroud a tissue for transplantation. Vacuum or pressure
of a hydrostatic pump impels the fluid and enshrouded tissue into the
tool and then into the eye. The tip of the surgical injector tool
curved in a direction extending distally away from a handle of the
surgical injector tool to better accommodate eye curvature.
Potential Commercial Applications:
Ocular tissue transplantation
Subretinal tissue transplantation
Delivery of extended release drug pellets into subretinal
space
Ocular surgery
Endothelial keratoplasty
Competitive Advantages:
Precision of operation for surgeon (no extra moving parts)
Instrument consists of separate disposable parts
Controlled delivery
Minimization of damage to the eye and transplanted tissue
Ease of operation
There is no available instrument capable to deliver tissue
into subretinal space
Development Stage:
Early-stage
In vivo data available (animal)
Prototype
Inventor: Arvydas Maminishkis (NEI).
Intellectual Property: HHS Reference No. E-192-2014/0--U.S.
Provisional Application No. 62/023,289 filed 11 July 2014.
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019;
[email protected]
Collaborative Research Opportunity: The National Eye Institute is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
ocular tissue transplantation device. For collaboration opportunities,
please contact Matthew McMahon at 301-451-1610 or
[email protected].
A Novel Demodulation System in X-ray Imaging
Description of Technology: In various x-ray imaging methods,
including scattering correction and phase contrast imaging, intensity
modulation in space is introduced into the projection images by the use
of masks, gratings, or apertures. The present invention relates to a
process to demodulate the modulation. The current demodulation
processes are either to remove the modulation pattern through digital
processing or to move the modulation pattern on the detector in a
series of images that requires mechanical movements of a component and
tends to lose some information of the imaged object. The demodulation
of the present invention can be realized with a relative movement
between the projected image of the sample and the modulation pattern
without having to move the modulation pattern. The demodulated images
are free of the modulation pattern and have better clarity.
Potential Commercial Applications:
Clinical diagnostic
Research tools
Security inspections
Competitive Advantages:
Better clarity for images
Simplify the demodulation method
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Han Wen and Houxun Miao (NHLBI)
Publications:
1. David C, et al. Interferometer for quantitative phase contrast
imaging and tomography with an incoherent polychromatic x-ray source.
U.S. Patent No. 7,889,838 issued 15 Feb 2011. [http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=7889838].
2. Schusser S, Vogtmeier G. Non-parallel grating arrangement with
on-the-fly phase stepping, x-ray system and use. PCT Application No.
PCT/IB2010/055562 filed 02 Dec 2010. [http://patentscope.wipo.int/search/en/WO2011070489].
Intellectual Property: HHS Reference No. E-113-2013/0--U.S.
Provisional Application No. 61/877,219 filed 12 Sep 2013.
Licensing Contact: John Stansberry, Ph.D.; 301-435-5236;
[email protected].
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize the technology. For collaboration
opportunities, please contact Dr. Denise Crooks at
[email protected].
A Novel X-ray Grating To Enhance Phase Contrast Imaging
Description of Technology: The present invention relates to
improving x-ray phase contrast imaging. The invention discloses a novel
grating interferometer for phase contrast imaging with hard x-rays that
overcomes limitations in the level of sensitivity by utilizing the
advantages of far-field interferometers. The novel design and
fabrication process can easily acquire absolute and differential
[[Page 54989]]
phase images of lightly absorbing samples.
Potential Commercial Applications:
Clinical diagnostics
Research tools
Competitive Advantages:
More sensitivity
Easier to fabricate images
Development Stage:
In vitro data available
In vivo data available (animal)
Inventor: Han Wen (NHLBI)
Publications:
1. Wen H. Boosting phase contrast with two-arm interferometers
using sub-micron period gratings. Presentation, The Royal Society,
London scientific discussion meeting: Taking x-ray phase contrast
imaging into mainstream applications, February 11, 2013, London, UK.
2. Momose A, Fukuda J. Phase-contrast radiographs of nonstained rat
cerebellar specimen. Med Phys. 1995 Apr;22(4):375-9. [PMID 7609717].
3. Clauser JF. Ultrahigh resolution interferometric x-ray imaging.
U.S. Patent No. 5,812,629 issued 22 Sep 1998. [http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=5812629].
Intellectual Property: HHS Reference No. E-114-2013/0--U.S.
Provisional Application No. 61/877,228 filed 12 Sep 2013.
Licensing Contact: John Stansberry, Ph.D.; 301-435-5236;
[email protected].
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize the technology. For collaboration
opportunities, please contact Dr. Denise Crooks at
[email protected].
Dated: September 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-21856 Filed 9-12-14; 8:45 am]
BILLING CODE 4140-01-P